Category Archives: Corporate

October wraps up healthcare IPOs with another strong week as 2018 biotech explosion still on record pace.

The News: The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development…. Read more »

Healthcare stocks bounce back Friday after really messy week, but still licking their wounds from recent global selloff.

After having their worst week in recent memory, with the NASDAQ HealthCare Index (IXHC) now down 8.6% since just Sept. 28, some healthcare stocks nonetheless blossomed with stupendous upswings. But… Read more »

Five more biotechs and one device maker close out 3rd quarter IPOs this week.

There are as many as five more biotech IPOs and one medical device maker pricing this week, raising up to $535 million. Even if two are postponed, it will still… Read more »

Flood gates for medical IPO filings still wide open as Labor Day holiday only speeds up pace for hopefuls.

The somber mood of summer’s waning days and shortened work week didn’t cool the blistering pace of biotech and other healthcare IPO news. Almost makes me feel sorry for the… Read more »

Weekly Medical Stock Spotlight: 3 big winners and 2 total duds.

1) ProQR Therapeutics NV (Nasdaq:PRQR) led advancing issues on the Labor Day-shortened week, soaring 107% over the week to $15.80 on Friday (August 31, 2018). The upward move came after the… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

India’s huge pharma/consumer health market in crosshairs of world’s biggest drugmakers. China, Japan, Korea lurking as Asia joins fray with West.

The News: GlaxoSmithKline PLC‘s (London) Indian consumer health unit is drawing the attention of more big-name suitors as the magnitude of the potential there is coming into clearer focus. After… Read more »

Korean push into biotech space meant to challenge China, as ViroMed buys US plant for new gene-therapy development. High risk/reward bet, only for the brave.

The News: ViroMed Co. Ltd., the Korean biotech, has seen companies miss out on approvals for novel therapies because the FDA had problems with their manufacturing processes. With its first treatment… Read more »